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Carbon ion radiotherapy holds great promise for cancer therapy. Clinical data show 
that carbon ion radiotherapy is an effective treatment for tumors that are resistant to 
X-ray radiotherapy. Since 1994 in Japan, the National Institute of Radiological Sciences 
has been heading the development of carbon ion radiotherapy using the Heavy 
Ion Medical Accelerator in Chiba. The Gunma University Heavy Ion Medical Center 
(GHMC) was established in the year 2006 as a proof-of-principle institute for carbon 
ion radiotherapy with a view to facilitating the worldwide spread of compact accelerator 
systems. Along with the management of more than 1900 cancer patients to date, 
GHMC engages in translational research to improve the treatment efficacy of carbon 
ion radiotherapy. Research aimed at guiding patient selection is of utmost importance 
for making the most of carbon ion radiotherapy, which is an extremely limited medical 
resource. Intratumoral oxygen levels, radiation-induced cellular apoptosis, the capacity 
to repair DNA double-strand breaks, and the mutational status of tumor protein p53 
and epidermal growth factor receptor genes are all associated with X-ray sensitivity. 
Assays for these factors are useful in the identification of X-ray-resistant tumors for 
which carbon ion radiotherapy would be beneficial. Research aimed at optimizing treat-
ments based on carbon ion radiotherapy is also important. This includes assessment 
of dose fractionation, normal tissue toxicity, tumor cell motility, and bystander effects. 
Furthermore, the efficacy of carbon ion radiotherapy will likely be enhanced by research 
into combined treatment with other modalities such as chemotherapy. Several clinically 
available chemotherapeutic drugs (carboplatin, paclitaxel, and etoposide) and drugs at 
the developmental stage (Wee-1 and heat shock protein 90 inhibitors) show a sensitiz-
ing effect on tumor cells treated with carbon ions. Additionally, the efficacy of carbon 
ion radiotherapy can be improved by combining it with cancer immunotherapy. Clinical 
validation of preclinical findings is necessary to further improve the treatment efficacy of 
carbon ion radiotherapy.
Keywords: carbon ion radiotherapy, patient selection, combination therapy, translational research, treatment 
planning
TABLe 1 | Clinical trails on carbon ion radiotherapy at GHMC.
Trial iD Patient 
enrollment
Cancer type Major indication criteria Total dose/fr. Combined therapy
Gunma0905 2012- Cranial base tumor No CNS invasion 60.8 GyRBE/16 fr. –
Gunma0901 2010–2013 H&N cancer (except Sq, 
melanoma, sarcoma)
N0/1M0 57.6 or 64 GyRBE/16 fr. –
Gunma0902 2012- H&N musculoskeletal tumor N0/1M0 70 GyRBE/16 fr. –
Gunma0903 2012- H&N melanoma N0M0 57.6 or 64 GyRBE/16 fr. Concurrent DTIC, 
ACNU, and VCR
Gunma0701 2010–2015 NSCLC Stage I, peripheral, inoperable 60 GyRBE/4 fr. –
Gunma1201 2013–2015 NSCLC Stage III, inoperable 40 GyRBE/10 fr. (ENI) + 20 or 
24 GyRBE/6 fr. (IFI)
–
Gunma0703 2010–2013 Hepatcellular carcinoma Tumor diameter ≤10 cm 52.8 GyRBE/4 fr. –
Gunma1203 2013 Hepatcellular carcinoma Tumor diameter 3–10 cm 60 GyRBE/4 fr. –
Gunma1303 2013–2015 Hepatcellular carcinoma Adjacent to digestive tract 60 or 64.8 GyRBE/12 fr. –
Gunma1301 2013–2015 Pancreatic cancer T4N0/1, inoperable 52.8 or 55.2 GyRBE/12 fr. Concurrent gemcitabine
Gunma1501 2015- Pancreatic cancer T4N0/1M0 55.2 GyRBE/12 fr. Concurrent S-1
Gunma0801 2010- Rectal cancer Postoperative local recurrence 73.6 GyRBE/16 fr. –
Gunma0702 2010–2013 Prostate cancer ≤T3 57.6 GyRBE/16 fr. ± Hormone therapy
Gunma1302 2013- Prostate cancer ≤T3 57.6 GyRBE/16 fr. ± Hormone therapy
Gunma1103 2013- Prostate cancer Castration resistant cancer 57.6 GyRBE/16 fr. ± Hormone therapy
Gunma1202 2013–2014 Uterine cervical cancer Locally advanced 36 GyRBE/12 fr. 
(WPI) + 19.2 GyRBE/4 fr. (IFI)
Concurrent CDDP 
followed by ICBT
Gunma1401 2014- Uterine cervical cancer Locally advanced 36 GyRBE/12 fr. 
(WPI) + 19.2 GyRBE/4 fr. (IFI)
Concurrent CDDP 
followed by ICBT
Gunma0904 2010–2013 Musculoskeletal tumors N0M0 64, 67.2, or 70.4 GyRBE/16 fr. –
Gunma1102 2011–2013 Musculoskeletal tumors 
(pediatric)
Age 6–16, inoperable 60.8, 64, 67.2, or 70.4 GyRBE/16 fr. –
Gunma1101 2011- Lymph node metastatic tumor 1–3 nodes in 1 irradiation field 48 or 52.8 GyRBE/12 fr. –
Gunma1304 2013- In-field recurrent tumor previously treated by 
radiotherapy
Various according to disease site –
Gunma1204 2013- Tumor resistant to standard Tx known to be resistant to 
standard Tx
Various according to disease site –
fr., fractions; CNS, central nervous system; H&N, head and neck; Sq, squamous cell carcinoma; NSCLC, non-small cell lung carcinoma; DTIC, dacarbazine; ACNU, nimustine; VCR, 
vincristine; ENI, elective nodal irradiation; IFI, involved field irradiation; WPI, whole pelvic irradiation; CDDP, cisplatin; ICBT, intracavitary brachytherapy; Tx, therapy.
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iNTRODUCTiON
Carbon ion radiotherapy holds great promise for cancer therapy. 
Carbon ions have two advantages over X-rays such as a sharp dose 
distribution and a strong cell-killing capacity (1). Clinical trials 
show that carbon ion radiotherapy has excellent antitumor effects 
(2, 3). Moreover, it is suggested that carbon ion radiotherapy is an 
effective treatment for tumors that are resistant to conventional 
X-ray radiotherapy (4–6).
The National Institute of Radiological Sciences (NIRS) initi-
ated carbon ion radiotherapy in Japan in the year 1994 using 
the Heavy Ion Medical Accelerator in Chiba (HIMAC). Up until 
January 2016, more than 8000 patients with different types of 
cancer were treated at the NIRS. The excellent clinical outcomes 
encouraged widespread use of carbon ion radiotherapy (2). 
However, the high cost of constructing the accelerator system 
limits its practical application. New accelerator systems were 
designed to overcome this limitation; as a result, the cost of the 
accelerator systems was reduced to approximately $100,000,000 
that accounts for one-third of the corresponding HIMAC param-
eters. Gunma University Heavy Ion Medical Center (GHMC) 
was launched in the year 2006 as a proof-of-principle institute 
for carbon ion radiotherapy based on the newly introduced 
compact accelerator systems. GHMC commenced operation of 
the accelerator systems in 2009 and performed the first carbon 
ion radiotherapy for cancer in 2010. All carbon ion radiotherapy 
carried out at GHMC has been performed as prospective clinical 
trial (Table 1). As of January 2016, GHMC has treated more than 
1900 cancer patients with carbon ion radiotherapy, without any 
major incidents.
Along with carbon ion radiotherapy, GHMC engages in 
translational research to improve the efficacy of this treatment 
modality with financial support from the Japan Society for 
the Promotion of Science through its two umbrella programs: 
the Twenty-First Century Centers of Excellence Program 
(2004–2008) and the Strategic Young Researcher Overseas 
Visits Program for Accelerating Brain Circulation (2013–2016). 
Translational research at GHMC was further accelerated by 
establishment of the Gunma University Initiative for Advanced 
Research in 2015, in which the Department of Radiation 
Oncology of the Massachusetts General Hospital/Harvard 
Medical School launched a Japanese branch to stimulate inter-
disciplinary collaboration in the field of heavy ion radiation 
biology. In addition, GHMC contributes to the education and 
development of global leaders in the field of heavy ion radiation 
therapy through the Program for Cultivating Global Leaders 
in Heavy Ion Therapeutics and Engineering, supported by the 
Japanese Ministry of Education, Culture, Sports, Science, and 
TABLe 2 | Number of cancer patients treated by carbon ion radiotherapy 
worldwide per year.
S. No. Country City Facility Case/year Year
1 Japan Chiba NIRS 888 2013
2 Japan Gunma GHMC 448 2013
3 Japan Hyogo HIBMC 270 2013
4 Japan Saga HIMAT 132 2013
5 China Lanzhou HIRFL 27 2006–2013 
in average
6 Germany Heidelberg HIT 274 2009–2013 
in average
7 Italy Pavia CNAO 53 2012–2013 
in average
NIRS, National Institute of Radiological Sciences; GHMC, Gunma University Heavy Ion 
Medical Center; HIBMC, Hyogo Ion-Beam Medical Center; HIMAT, Heavy Ion Medical 
Accelerator in Tosu; HIRFL, Heavy Ion Research Facility in Lanzhou; HIT, Heidelberg 
Ion-Beam Therapy Center; CNAO, Centro Nazionale Adroterapia Oncologica.
Data on facility #1–4 are based on the website of Association for Nuclear Technology in 
Medicine (written in Japanese): http://www.antm.or.jp/05_treatment/01.html. Data on 
facility #5–7 are based on Ref. (8).
FiGURe 1 | Tools for intratumoral pO2 measurement. A needle-type 
polarographic oxygen electrode is used by direct insertion into a tumor.
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Technology (2012–2018). Here, we summarize achievements in 
translational research on carbon ion radiotherapy performed at 
GHMC through these scientific endeavors.
ReSeARCH TO GUiDe THe SeLeCTiON 
OF PATieNTS SUiTABLe FOR CARBON 
iON RADiOTHeRAPY
The number of newly diagnosed cancer patients worldwide is ~14 
million/year (7). By contrast, the maximum number of patients 
that can be treated by carbon ion radiotherapy worldwide is 
estimated to be ~2100/year (Table  2) (8). Thus, carbon ion 
radiotherapy has the capacity to treat only 0.015% of the total 
patient population with a newly diagnosed cancer. Moreover, 
even in Japan, which has the highest density of facilities for 
carbon ion radiotherapy in the world, carbon ion radiotherapy 
has the capacity to treat only 0.20% of newly diagnosed cancer 
cases. These facts highlight the extremely limited availability 
of this medical resource. Although 11 facilities for carbon ion 
radiotherapy are currently under construction or are planned 
for construction (1), the critical shortage of facilities will not 
be resolved in any practical way for a few decades. Therefore, 
selecting patients who can derive the greatest benefit from 
carbon ion radiotherapy is of great importance. Early clinical 
experience shows that carbon ion radiotherapy is an effective 
treatment for tumors that are resistant to conventional X-ray 
radiotherapy (4–6); therefore, carbon ion radiotherapy will be 
the most beneficial for patients with these types of tumor. From 
this point of view, assays that predict the X-ray sensitivity of a 
tumor are urgently required to facilitate appropriate selection of 
patients for carbon ion radiotherapy.
Histopathological typing of tumors is performed to predict 
treatment responses in the clinical setting of X-ray radiotherapy. 
Nevertheless, the response varies widely according to tumor type, 
and even among those with the same histological type. Thus, 
additional indices that support prediction of X-ray sensitivity 
according to histopathological type are required. For many 
types of cancer, the SF2 value, i.e., the surviving fraction of 
X-irradiated tumor cells (irradiated ex vivo with a dose of 2 Gy) 
measured in a clonogenic survival assay, correlates with clinical 
outcome of X-ray radiotherapy (9). However, the SF2 value has 
shortcomings, i.e., primary culture of the tumor cells required 
for the clonogenic assay is difficult, and necessitates 2 weeks to 
obtain final results. Therefore, the SF2 value is not widely used 
in the clinic. Previously, we identified several cellular mecha-
nisms that contribute to the resistance of cancer cells to X-rays, 
including intratumoral hypoxia, resistance to radiation-induced 
apoptosis, a high capacity for the repair of DNA double-strand 
breaks (DSBs), and mutations in certain oncogene and tumor 
suppressor genes. By focusing on these factors, we propose the 
following predictive assays for determining the X-ray sensitivity 
of cancer cells.
Intratumoral hypoxia is a major contributor to the X-ray resist-
ance of cancer cells (10–12). Nakano et  al. used a needle-type 
polarographic oxygen electrode to measure intratumoral oxygen 
partial pressure (pO2) in patients with locally advanced uterine 
cervical cancer treated using X-ray radiotherapy (13) (Figure 1). 
The authors found that low pretreatment intratumoral pO2 values 
correlated with poor outcomes after X-ray radiotherapy. On the 
other hand, carbon ion radiotherapy showed good antitumor 
effects in patients with locally advanced uterine cervical cancer, 
irrespective of pretreatment intratumoral pO2 levels. These data 
indicate that assays to determine pretreatment intratumoral pO2 
values will be useful for identification of X-ray-resistant tumors 
profiting from carbon ion radiotherapy. Importantly, recent stud-
ies indicate that as many as 50% of tumors have hypoxic regions, 
which could underpin X-ray treatment failure and expand the 
indications for carbon ion radiotherapy (14). Cancer cell resist-
ance to radiation-induced apoptosis is another major factor 
that contributes to X-ray resistance. Preclinical studies suggest 
that carbon ions effectively kill cancer cells that are resistant to 
apoptosis induced by X-ray irradiation (15, 16). Another mode 
FiGURe 3 | Radiation-induced DSBs visualized by 
immunofluorescence staining of γH2AX and 53BP1. Cultured A549 lung 
cancer cells were immunostained for γH2AX and 53BP1 at 30 min or 24 h 
post-irradiation using X-rays at a dose of 1 Gy. DSBs are identified as foci of 
γH2AX and 53BP1. Merged images show high consistency between γH2AX 
foci and 53BP1 foci. A markedly smaller number of γH2AX and 53BP1 foci at 
24 h compared with 30 min indicate the high capacity of the X-ray-resistant 
cell line for DSB repair.
FiGURe 2 | Radiation-induced apoptosis, as assessed by DAPi 
staining. Cultured Ma-24 lung cancer cells were stained with DAPI at 72 h 
after irradiation using X-rays at a dose of 4 Gy. Apoptotic cells are identified 
by the appearance of apoptotic bodies, characterized by condensed and 
fragmented nuclei, under a fluorescence microscope.
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of clonogenic cell death, called mitotic catastrophe and necro-
sis, is involved in efficient killing of apoptosis-resistant cancer 
cells by carbon ions (15, 16). Apoptosis following irradiation is 
readily assessed by morphological observation of nuclei stained 
with 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI) 
(Figure 2). Amornwichet et al. demonstrated that apoptosis in 
HCT116 colon cancer cells peaked at 72  h post-X-ray irradia-
tion, as assessed by DAPI staining (16). This is consistent with 
the observation that radiation-induced apoptosis in solid tumors 
mainly corresponds to the so-called late apoptosis, which occurs 
a few days post-irradiation (17). Furthermore, the DAPI-based 
assay is easier and faster to perform than the clonogenic survival 
assay used to calculate the SF2 value. Therefore, DAPI staining 
of ex vivo-irradiated tumor specimens at 72  h post-irradiation 
is useful for identifying tumors that are resistant to X-ray-
induced apoptosis and would therefore benefit from carbon ion 
radiotherapy.
Double-strand breaks are major cytotoxic lesions that cause 
cancer cell death after exposure to ionizing radiation (17). 
Preclinical studies indicate that the high capacity of cancer 
cells for DSB repair contributes to X-ray resistance (18, 19). 
Meanwhile, the cell-killing actions of carbon ions are less 
affected by intrinsic DSB repair capacity (18, 19). Most likely, 
complex carbon ion-induced DSBs are more difficult to repair 
than X-ray-induced DSBs; these persistent unrepaired DSBs then 
lead to mitotic catastrophe (16). These data indicate that tumors 
with a high capacity for DSB repair are suitable for carbon ion 
radiotherapy. DSB repair capacity can be evaluated by immuno-
fluorescence staining for Ser139-phosphorylated histone H2AX 
(γH2AX) or p53-binding protein 1 (53BP1) because DSBs are 
detected as foci of γH2AX or 53BP1 (Figure  3) (20–22). The 
number of foci at 30 min post-irradiation can be used as an index 
for radiation-induced DSBs. On the other hand, the number of 
foci in irradiated cells decreases by more than 90% within 24 h 
post-irradiation, indicating that a major proportion of radiation-
induced DSBs is repaired by that time point (20). Thus, the ratio 
of the foci number at 24  h post-irradiation to that at 30  min 
post-irradiation can be used as an index for DSB repair capacity. 
Importantly, the high DSB repair capacity (as indicated by low 
number of foci at 24 h post-irradiation) is associated with a high 
rate of clonogenic survival (19). Hence, assay of γH2AX or 53BP1 
foci in ex vivo-irradiated tumor specimens can be performed to 
identify tumors with a high capacity for DSB repair and suitable 
for carbon ion radiotherapy.
Cancer cells harbor modifications in a number of molecular 
pathways that affect intrinsic radiosensitivity. Mutations in 
oncogenes and tumor suppressor genes are common, and these 
mutations result in alterations in signaling pathways. We previ-
ously showed that inactivating mutations in the gene encoding 
tumor suppressor protein 53 (TP53) confer X-ray resistance on 
cancer cells (15, 16, 23). We also showed that epidermal growth 
factor receptor gene (EGFR) mutation-negative non-small cell 
lung cancer (NSCLC) cells are more resistant to X-rays than 
EGFR mutation-positive NSCLC cells (19). These findings were 
validated by clinical studies (24–27). Interestingly, investiga-
tions using isogenic cancer cell lines demonstrated that carbon 
ions can kill cancer cells irrespective of the mutational status 
of TP53 and EGFR (15, 16, 19, 23). Taken together, these data 
indicate that the mutational status of TP53/EGFR is useful for 
selecting patients who are suited for carbon ion radiotherapy. 
Nevertheless, a recent genome-wide analysis revealed the pres-
ence of hundreds of gene mutations in a single tumor (28). 
Because the overall radiosensitivity of a tumor should be the 
result of this highly complex genetic context, the mutational 
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status of only a small subset of well-known cancer-related 
genes (e.g., TP53 and EGFR) may not be the best predictor 
of radiosensitivity. Thus, studies aimed at elucidating detailed 
gene mutation profiles to facilitate better prediction of tumor 
radiosensitivity are warranted.
ReSeARCH AiMeD AT OPTiMiZiNG 
CARBON iON RADiOTHeRAPY
Optimization of carbon ion radiotherapy can be addressed using 
two approaches such as radiation physics and radiation biology. 
Both physics and biology play intertwining roles in treatment 
planning; therefore, advances in one field benefit the other. For 
example, increased irradiation accuracy results in less normal 
tissue toxicity. By contrast, accurate information about the bio-
logical characteristics of tumors and normal tissues aids optimal 
treatment planning. Biological factors that affect the treatment 
procedure, including biological responses to dose fractionation, 
normal tissue toxicity, tumor cell motility, and the bystander 
effect, are discussed below.
In X-ray radiotherapy, the rationale for dose fractionation is 
provided by the re-oxygenation and cell cycle redistribution of 
tumor cells, as well as a higher capacity for the repair of sublethal 
damage in normal tissues versus tumors (17). The cell-killing 
effect of carbon ions versus X-rays is less dependent on these 
factors (13, 17); therefore, the responses of tumors and normal 
tissues to carbon ions may be different from those to X-rays, 
even when the same dose fractionation schedule is utilized. To 
address this issue, Ando et al. used a mouse model to explore the 
effects of carbon ion dose fractionation on tumor and normal 
tissues (29). The investigators treated fibrosarcoma xenografts 
and host mouse skin with γ rays or carbon ion beams with 
three different linear energy transfer (LET) values (20, 42, and 
77 keV/μm) and with different fractionation schedules (i.e., one 
to seven fractions). Interestingly, the relative biological effective-
ness (RBE) values for tumor growth delay were higher than those 
for early skin reaction when 42- and 77-keV/μm carbon ion 
beams, but not γ rays or 20-keV/μm carbon ion beams, were 
employed in intermediate fractionation schedules (i.e., two to 
six fractions). The therapeutic gain (calculated as the ratio of 
the RBE value for tumor growth delay to that for early skin 
reaction) was maximized for the 42  keV/μm beams delivered 
in four fractions. Yoshida et al. examined the impact of carbon 
ion dose fractionation on the small intestine by assessing crypt 
survival in the mouse model employed above (30). In contrast 
to the results for early skin reaction, no therapeutic gain was 
observed for the intermediate fractionation schedules. This 
might be because intestinal crypt cells have a low capacity to 
repair sublethal damage induced by carbon ions. These two stud-
ies indicate that different strategies are required to optimize the 
dose fractionation schedules used for carbon ion radiotherapy in 
the skin versus the small intestine. With respect to the skin, the 
therapeutic window for carbon ion irradiation can be expanded 
by employing an intermediate hypofractionation strategy. 
Therefore, the actual fractionation schedule that corresponds to 
“intermediate” hypofractionation in the mouse model should be 
further explored in the clinic. On the other hand, the therapeutic 
window for carbon ions and X-rays in the small intestine may 
be comparable, and the benefit of dose fractionation may be 
lower for carbon ions than for X-rays. This indicates that, in 
abdominal irradiation to treat tumors such as uterine cervical 
cancer, the maximum tolerable carbon ion dose can be delivered 
in a smaller number of fractions, resulting in a shorter treatment 
period. In addition, hypofractionated carbon ion radiotherapy 
that results in the shorter treatment period compared with X-ray 
radiotherapy utilizing conventional 2 Gy/day fractionation can 
contribute to reduce tumor repopulation effect. Assessment of 
the effect of carbon ion dose fractionation in different tumors 
and normal tissues in the same mouse model should be further 
investigated, together with concomitant evaluation of factors 
that can affect the results of fractionated irradiation (i.e., oxygen 
levels, cell cycle profiles, and DSB repair capacity).
Carbon ion radiotherapy shows a steep dose fall-off; there-
fore, the treatment plans are more susceptible to target motion 
than the plan for three-dimensional conformal radiotherapy 
(3D-CRT) with X-rays. A larger target volume setting increases 
the robustness of the dose delivered to the tumor; however, it 
also increases toxicity to adjacent normal tissues. Therefore, it 
is necessary to determine the sensitivity of normal tissues to 
obtain the optimal target volume setting. The nervous system 
is critically at risk of radiotherapy toxicity, because it is a serial 
organ with low redundancy and low capacity for regeneration. 
The sensitivity of the central nervous system to carbon ions 
has been examined in multiple experimental models. Isono 
et  al. evaluated the sensitivity of human neural stem cells to 
carbon ions and found that the RBE value, as assessed by cell 
proliferation, was 2.0 (31). Yoshida et  al. examined the effects 
of carbon ion irradiation in normal rat brain (32). The authors 
used an organotypic slice culture of cerebellum excised from 
10-day-old rats and assessed morphological changes and cellular 
apoptosis, defined as disorganization of the external granule 
cell layer and positive staining for TdT-mediated dUTP-biotin 
nick-end labeling (TUNEL), respectively. They found that the 
RBE value for rat cerebellum was 1.4–1.5. Kaminuma et  al. 
also explored carbon ion-provoked apoptosis in the rat brain 
by performing a TUNEL assay in a primary culture of fetal 
hippocampal neurons (33). The RBE value was strikingly high 
at 10.2. Similarly, Al-Jahdari and colleagues investigated the 
sensitivity of the peripheral nervous system to carbon ions by 
employing dorsal root ganglia and sympathetic ganglion chains 
prepared from the chick embryo at days 8 and 16, represent-
ing the immature and mature peripheral nervous system (34). 
Growth cone collapse was assessed as an index of malfunction 
in the neuronal network, yielding an RBE value of 3.1–3.2 in 
day 8 neurons and 1.5–2.1 in day 16 neurons. Meanwhile, the 
RBE value assessed by TUNEL staining was 2.5–2.9 in day 8 
neurons and 1.4–1.8 in day 16 neurons. Although it is difficult 
to draw a firm conclusion from the above studies employing 
different experimental models, nervous systems (central and 
peripheral) and endpoints, the data collectively indicate that 
the RBE value of the adult nervous system is ~1.4–2.1 when 
morphological changes and cellular apoptosis are utilized as 
endpoints. Given the fact that the RBE value for carbon ions in 
cancer cells is generally ~2–3, these findings suggest that carbon 
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ion radiotherapy has a wider therapeutic window than X-rays 
when used to treat tumors adjacent to the components of the 
central and peripheral nervous systems. Notably, these data also 
indicate that immature neurons are more sensitive to carbon ion 
irradiation than mature neurons. Thus, careful attention should 
be paid to neural toxicity when carbon ion radiotherapy is used 
to treat pediatric tumors.
The lung is another critical organ at risk in radiotherapy. 
Radiation-induced lung injury can be lethal in some patients 
and is a major dose-limiting factor for thoracic irradiation (35). 
Okano et al. used a crystal violet staining assay to examine the 
effect of carbon ions on the proliferation of immortalized human 
small airway epithelial cells (iSAECs) and normal human lung 
fibroblasts (36). The resultant RBE value was 3.2 for iSAECs 
and 2.2 for normal lung fibroblasts. On the other hand, ionizing 
radiation can indirectly damage normal lung tissue by triggering 
inflammatory reactions. Upregulation of intercellular adhesion 
molecule-1 (ICAM-1) expression on the surface of pulmonary 
endothelial cells participates in this inflammation-related pro-
cess by increasing macrophage infiltration into the lung (37, 38). 
Kiyohara et  al. compared ICAM-1 expression on the surface 
of human umbilical vein endothelial cells after irradiation with 
carbon ions and X-rays. The data showed that post-irradiation 
ICAM-1 expression levels were 2.56- and 2.47-fold higher after 
carbon ion irradiation than after X-ray irradiation at 1 and 
2  Gy, respectively (39). These data signify that the estimated 
RBE values in normal lung tissue and lung cancer cells are 
comparable (~2–3) (19).
Several studies demonstrate that X-ray irradiation increases 
the motility of cancer cells (40, 41). The migration of irradiated 
cancer cells may influence the setting of target volumes, i.e., 
the margin from the gross tumor volume (GTV) to the clinical 
target volume (CTV). Murata et al. used a wound healing assay 
and F-actin staining to examine the effect of carbon ions on the 
motility of A549 lung cancer cells (42). Carbon ion irradiation 
promoted the healing of scratch wounds in cell monolayers and 
increased the formation of F-actin protrusions, both indicators of 
increased cancer cell motility. Interestingly, the RBE value based 
on cell motility was consistent with that based on cell survival 
(i.e., ~4 versus 3.9). This finding provides important insight into 
treatment planning, i.e., the GTV–CTV margin can be set in a 
comparable manner for X-rays and carbon ions.
The bystander effect is a phenomenon whereby non-irradiated 
cells adjacent to irradiated cells are killed (43). Previous research 
shows that the bystander effect is universal among most types of 
normal cells and tumor cells (43). However, the significance of 
the bystander effect among different types of cells after carbon 
ion irradiation is not fully understood. Harada et al. investigated 
the bystander effect in carbon ion-irradiated A549 cells by using 
carbon ion microbeams (diameter =  20 μm) to irradiate only 
0.0001–0.002% of the cells in a culture plate (44). The entire 
cell population was then subjected to a clonogenic survival 
assay, resulting in an 8–14% reduction in cell survival. Thus, the 
bystander effect plays a highly significant role in carbon ion-
induced killing of A549 lung cancer cells. By contrast, Wakatsuki 
et al. found that the bystander effect played no role in the killing 
of a HTB-94 chondrosarcoma cell line (45). These data highlight 
the fact that different cell types show different susceptibilities 
to the bystander effect induced by carbon ion irradiation by up 
to ~10%. Further research into the carbon ion radiotherapy-
induced bystander effects in different tumor cells and normal 
cells is necessary to optimize treatment planning.
ReSeARCH iNTO COMBiNATiON 
THeRAPY TO eNHANCe THe eFFiCACY 
OF CARBON iON RADiOTHeRAPY
Theoretically, a sufficiently high dose of ionizing radiation can 
sterilize any type of tumor (46). However, clinically applicable 
doses are delivered within a range that is tolerable by normal 
tissues (47). Dose escalation trials are underway to identify the 
maximum tolerable dose for carbon ion radiotherapy according 
to disease site (2). To date, clinical experience indicates that 
carbon ion radiotherapy can be delivered to many disease sites at 
higher biologically equivalent doses than 3D-CRT using X-rays. 
Carbon ion radiotherapy can also achieve nearly 100% tumor 
control probability in tumors that are uncontrollable by other 
radiation therapy modalities using X-rays and protons, such 
as spinal chordomas (1). Nonetheless, local recurrence occurs 
within the GTV, indicating the presence of a subset of carbon 
ion-resistant tumors.
To eradicate carbon ion-resistant tumors, it is important 
to establish an optimal form of combination treatment that 
increases the efficacy of carbon ion radiotherapy. To this end, 
several clinically available chemotherapeutic drugs have been 
tested in a preclinical setting. Kubo et  al. examined the ability 
of carboplatin and paclitaxel to sensitize H460 lung cancer cells 
to carbon ion beams (48). Both sensitized cancer cells to carbon 
ion irradiation, with sensitizing ratios of 1.21 and 1.22, respec-
tively (NB, a sensitizing ratio of >1 indicates that the radiation 
and the drug have a synergistic effect). These sensitizing ratios 
were comparable with those of X-rays. Similarly, Takahashi et al. 
demonstrated that etoposide sensitized X-ray-resistant rat yolk 
sac tumor cells to carbon ions, reporting a sensitizing ratio of 
~1.2 (23). Carboplatin, paclitaxel, and etoposide are all currently 
used in combination with X-rays for clinical tumor treatment; 
carboplatin and paclitaxel are used to treat NSCLC, uterine 
cervical cancer, and esophageal cancer, and etoposide is used to 
treat small cell lung cancer. The combination of these drugs with 
carbon ions should likewise be tested in the clinic.
Several drugs currently under development have been tested 
for their ability to sensitize cells to carbon ion irradiation. Ma and 
colleagues examined the sensitizing effects of the Wee-1 inhibitor, 
MK-1775, using H1299 lung cancer cells (49). Wee-1 is a nuclear 
kinase protein involved in activating the G2 cell cycle checkpoint. 
Pretreatment for lung cancer cells with MK-1775 abrogated the 
induction of G2/M arrest after carbon ion irradiation, leading 
to an increase in mitotic catastrophe-mediated cell death. The 
sensitizing ratio of MK-1775 was 1.21 at 200 nM, a concentration 
at which MK-1775 alone reduces the surviving cell fraction by 
50%. Musha et al. evaluated the sensitizing effect of the heat shock 
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protein 90 (Hsp90) inhibitor, 17-AAG, in LMF4 oral squamous 
cell carcinoma cells (50). Hsp90 forms a chaperone complex with 
client proteins, thereby stabilizing them. Because various Hsp90 
client proteins [e.g., Akt, ErbB2, and hypoxia-inducible factor-
1α (HIF-1α)] are associated with malignant cancer phenotypes, 
Hsp90 is regarded as a potent molecular target (51–53). 17-AAG 
sensitized tumor cells to carbon ions with a sensitizing ratio of 
1.14 at 100 nM, a concentration at which 17-AAG alone reduces 
the surviving cell fraction by 30–40%, although the underlying 
mechanism is unclear. These data indicate that Wee-1 or Hsp90 
inhibition is a viable strategy for sensitization of carbon ions, but 
the sensitizing effect requires further testing in animal models. 
As a monomodality treatment for cancer, MK-1775 is currently 
under investigation in phase I and phase II clinical trials (54). 
Meanwhile, a phase II clinical trial for 17-AAG was terminated 
due to the lack of adequate tumor response and the presence 
of normal tissue toxicity (55). Nevertheless, a number of next-
generation Hsp90 inhibitors are now being tested in multiple 
clinical trials (55).
Cancer immunotherapy has recently provoked a great deal 
of interest. Novel molecular targeting therapies (including those 
targeting programed cell death 1, programed cell death-ligand 
1, and cytotoxic T-lymphocyte-associated protein 4) all dem-
onstrate marked antitumor effects (56–58). Evidence suggests 
that the antitumor immune response plays an important role 
in the antitumor efficacy of X-ray radiotherapy. Nakano et  al. 
showed that pretreatment levels of intratumoral infiltration 
by Langerhans cells and T cells, the key players in antitumor 
immune responses, correlates with a favorable outcome in 
patients with uterine cervical cancer treated using X-ray 
radiotherapy (59). They also showed that concomitant use of 
X-rays and intratumoral injection of sizofiran, an immune-
response modifying drug, increases intratumoral infiltration 
of Langerhans cells and T-cells in patients with uterine cervi-
cal cancer (60). Recently, Suzuki et  al. demonstrated that an 
antigen-specific T cell response is activated in esophageal 
cancer patients receiving combined X-ray radiotherapy and 
chemotherapy (61). These data suggest that the efficacy of X-ray 
radiotherapy can be improved upon combination with assorted 
cancer immunotherapies.
To investigate whether the antitumor immune response 
contributes to the antitumor efficacy of carbon ion radiotherapy, 
Yoshimoto et al. examined the impact of carbon ion irradiation 
on the release of high-mobility group box 1 protein (HMGB1) 
after irradiation in various cancer cell lines (62). HMGB1 is 
released from tumor cells damaged by radiotherapy and/or 
chemotherapy. Elevated serum HMGB1 levels are associated 
with activation of the antigen-specific T cell responses after 
chemoradiotherapy (61). The investigators found that HMGB1 
levels in conditioned culture media were significantly higher after 
carbon ion irradiation. The RBE values based on HMGB1 release 
were similar to those based on clonogenic survival. These data 
suggest that the antitumor immune response contributes to an 
antitumor effect not only in X-ray radiotherapy but also in carbon 
ion radiotherapy. Additional preclinical research investigating 
the effects of combinations of carbon ion radiotherapy and cancer 
immunotherapy is currently underway.
PeRSPeCTiveS
Carbon ion radiotherapy is a promising therapy for cancer. 
Appropriate patient selection based on individual tumor radio-
sensitivity is key to making the most of this medical resource 
with extremely limited availability. Recent advances in molecular 
biology research emphasize the need for functional predictive 
assays using tumor biopsy specimens for the practice of precision 
medicine (63). The utility of predictive assays for determining 
intratumoral oxygen levels, radiation-induced cellular apopto-
sis, DSB repair capacity, and gene mutational status should be 
tested in the clinic. Of note, recent studies demonstrate that a 
combination of distinct tumor features can work synergistically 
to predict prognosis in a subset of tumors, indicating the benefit 
of combined usage of these predictive assays (64). In addition, 
progress in the field of metabolomics indicates that non-invasive 
predictive assays based on biofluids, such as blood or urine, will 
be established in the near future (65, 66).
Researchers have accumulated extensive data concern-
ing radiobiological properties of cancers and normal tissues. 
However, translation of biological data to the clinic remains far 
from satisfactory. This may be partially due the huge diversity in 
experimental systems used in radiation biology studies, making 
it difficult to draw solid conclusions for clinical applications. 
A meta-analytic approach to integrate the existing data is sug-
gested. Moreover, specification of carbon ion beams including 
LET values employed in the studies must be carefully considered 
during the data translation process. Most in  vitro studies used 
mono-energetic high-LET (i.e., ~100 keV/μm) carbon ion beams. 
However, several facilities, including NIRS and GHMC, now 
utilize spread-out Bragg peak (SOBP) carbon ion beams, which 
comprise a mixture of different LET beams, in the clinic. The 
biological effect of SOBP carbon ion beams likely differs from 
that of mono-energetic high-LET beams. Studies during the 
early era of carbon ion radiobiology provide plenty of data on 
the biological effect of SOBP carbon ion beams. Nevertheless, 
these data are difficult to interpret in the context of modern 
molecular biology and in a clinical setting because the biological 
effects were analyzed using biophysics models to deconvolute the 
mixed LET spectrum. Therefore, future studies should investigate 
the effects of SOBP carbon ion beams using current molecular 
biological techniques, particularly with respect to tumor hypoxia, 
radiation-induced apoptosis, and DSB repair.
Emerging molecular biology techniques are expected to con-
tribute to further advancement of translational research in carbon 
ion radiobiology. First, next-generation sequencing technologies 
will almost certainly identify specific genomic and epigenomic 
profiles that affect radiosensitivity (28, 67) and can be combined 
with existing data concerning expression profiles related to 
radiosensitivity (68, 69). Second, advanced high-resolution 
microscopy techniques will clarify the molecular processes that 
occur following carbon ion irradiation. For example, Britton et al. 
visualized recruitment of a single Ku molecule at DSB sites, which 
is essential for the repair of DSBs induced by ionizing irradiation 
(70). Thus, advanced high-resolution microscopy will promote 
our understanding of the repair kinetics of complex DSBs 
induced by carbon ions. Third, emerging imaging technologies 
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will enable detailed visualization of intratumoral oxygen levels 
and metabolomic states (71). We anticipate that integration and 
translation of data in radiation biology will greatly improve the 
efficacy of carbon ion radiotherapy.
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